Get the Stockscreener App
15.00
3.85%
-0.60
After Hours:
15.00
Organon Co stock is traded at $15.00, with a volume of 3.40M.
It is down -3.85% in the last 24 hours and up +2.04% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$15.60
Open:
$15.4
24h Volume:
3.40M
Relative Volume:
1.05
Market Cap:
$3.87B
Revenue:
$6.41B
Net Income/Loss:
$1.30B
P/E Ratio:
2.9762
EPS:
5.04
Net Cash Flow:
$646.00M
1W Performance:
+3.81%
1M Performance:
+2.04%
6M Performance:
-26.07%
1Y Performance:
-17.90%
1-Day Range:
$15.00
$15.50
1-Week Range:
$14.26
$16.08
52-Week Range:
$13.87
$23.10
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
15.00 | 3.87B | 6.41B | 1.30B | 646.00M | 5.04 |
|
LLY
Lilly Eli Co
|
821.86 | 781.10B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
212.06 | 374.36B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.85 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
74.79 | 332.00B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
93.35 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon’s SWOT analysis: stock poised for growth amid challenges - Investing.com India
Trend Tracker for (OGN) - Stock Traders Daily
Proficio Capital Partners LLC Acquires New Holdings in Organon & Co. (NYSE:OGN) - Defense World
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older - BioSpace
MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO - Quantisnow
Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune
Organon announes results from analysis of Phase 3 ADORING 3 study - TipRanks
Smartleaf Asset Management LLC Raises Holdings in Organon & Co. (NYSE:OGN) - Defense World
Can This Skin Treatment Work for Months After Stopping? New Clinical Data Reveals Surprising Results - StockTitan
Organon and Partners Advance Women’s Health Innovation to Drive Economic and Social Growth in Southeast Asia - The Hastings Tribune
Organon and partners drive innovation to strengthen healthcare access - Bangkok Post
Organon & Co. (NYSE:OGN) Shares Sold by Private Advisor Group LLC - Defense World
Truist Financial Corp Increases Stock Holdings in Organon & Co. (NYSE:OGN) - Defense World
(OGN) Long Term Investment Analysis - Stock Traders Daily
Principal Financial Group Inc. Raises Stock Position in Organon & Co. (NYSE:OGN) - MarketBeat
New York State Common Retirement Fund Buys 43,928 Shares of Organon & Co. (NYSE:OGN) - MarketBeat
Organon & Co. (NYSE:OGN) Shares Up 5.7%Here's What Happened - MarketBeat
A&I Financial Services LLC Invests $402,000 in Organon & Co. (NYSE:OGN) - MarketBeat
Is Organon & Co. (OGN) the Best Low Price Pharma Stock to Invest In Right Now? - Insider Monkey
New York State Common Retirement Fund Increases Stake in Organon & Co. (NYSE:OGN) - Defense World
Rhumbline Advisers Sells 14,051 Shares of Organon & Co. (NYSE:OGN) - Defense World
Principal Financial Group Inc. Buys 32,485 Shares of Organon & Co. (NYSE:OGN) - Defense World
The Hidden Gems of the Pharma World: Stocks Analysts Can’t Ignore - jomfruland.net
Organon & Co. (OGN): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts - Insider Monkey
10 Cheap Pharmaceutical Stocks to Buy According to Analysts - Insider Monkey
Allspring Global Investments Holdings LLC Increases Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
New York State Teachers Retirement System Has $4.61 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World
Savant Capital LLC Sells 88,315 Shares of Organon & Co. (NYSE:OGN) - MarketBeat
Organon's SWOT analysis: women's health leader faces biosimilar growth, LOE challenges - MSN
Organon announces departure of chief commercial officer - MSN
Philip James Wealth Mangement LLC Has $12.99 Million Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga India
Organon & Co. Navigates Growth Amidst Challenges - TipRanks
Long Term Trading Analysis for (OGN) - Stock Traders Daily
Organon & Co. Declares Quarterly Dividend of $0.28 (NYSE:OGN) - MarketBeat
Van ECK Associates Corp Has $7.90 Million Position in Organon & Co. (NYSE:OGN) - Defense World
Organon & Co. (NYSE:OGN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Organon & Co. (NYSE:OGN) Shares Down 5.9% on Disappointing Earnings - MarketBeat
Organon & Co. (NYSE:OGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Organon's (NYSE:OGN) Dividend Will Be $0.28 - Simply Wall St
Organon (NYSE:OGN) Will Pay A Dividend Of $0.28 - Yahoo Finance
Barclays Cuts Organon & Co. (NYSE:OGN) Price Target to $24.00 - Defense World
36,323 Shares in Organon & Co. (NYSE:OGN) Acquired by Kingsview Wealth Management LLC - MarketBeat
Organon & Co. (NYSE:OGN) Announces Earnings Results, Misses Expectations By $0.09 EPS - MarketBeat
Organon sets 2025 revenue guidance range below consensus - MSN
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):